Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

AMLX 01.10.2025

Full Press ReleaseSEC FilingsOur AMLX Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis
  • 01.10.2025 - Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  • 01.10.2025 - Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

Recent Filings

  • 01.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
  • 01.10.2025 - 424B5 Prospectus [Rule 424(b)(5)]
  • 01.10.2025 - 8-K Current report

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 9, 2025--Amylyx Pharmaceuticals, Inc.(Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Amylyx. In addition, Amylyx intends to grant the underwriter a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares offered in the public offering at the public offering price per share, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Amylyx intends to use the net proceeds from this offering, together with existing cash, cash equivalents and marketable securities, to advance preparations for commercialization and pipeline programs, for working capital and for general corporate purposes.

Leerink Partnersis acting as sole book-running manager for the offering.

The shares described above are being offered pursuant to an automatically effective shelf registration statement on Form S-3 (File No. 333-270505) that was filed with theSecurities and Exchange Commission(“SEC”) onMarch 13, 2023. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with theSECand will be available on the SEC’s website atwww.sec.gov. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may also be obtained by contacting:Leerink Partners LLC,Syndicate Department,53 State Street, 40th Floor,Boston, MA02109, or by telephone at (800) 808-7525 ext. 6105, or by email atsyndicate@leerink.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of that state or jurisdiction.

AboutAmylyx Pharmaceuticals

Amylyx is committed to the discovery and development of new treatment options for communities with high unmet needs, including people living with serious and fatal neurodegenerative diseases and endocrine conditions. Since its founding, Amylyx has been guided by science to address unanswered questions, keeping communities at the heart and center of all decisions. Amylyx is headquartered inCambridge, Massachusetts.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including with respect to Amylyx’ intention to conduct an offering and sale of securities, the completion of the proposed offering, the expectation to grant the underwriter a 30-day option to purchase additional shares and the expected use of proceeds from the proposed offering. No assurance can be given that the offering discussed above will be completed. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include those risks and uncertainties set forth in Amylyx’SECfilings, including Amylyx’ Annual Report on Form 10-K for the year endedDecember 31, 2023, Quarterly Report on Form 10-Q for the quarterly period endedSeptember 30, 2024and its subsequent filings with theSEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Amylyx.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20250109174588/en/

MediaAmylyx Media Team+1 (857) 799-7274amylyxmediateam@amylyx.com

InvestorsLindsey AllenAmylyx Pharmaceuticals, Inc.+1 (857) 320-6244Investors@amylyx.com

Source:Amylyx Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com